These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35981078)

  • 1. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
    Cheng Y; Xue Y; Chen L; Masin M; Maciag P; Peluso T; Zhou S; Li Y
    Br J Clin Pharmacol; 2023 Jan; 89(1):316-329. PubMed ID: 35981078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.
    Cheng Y; Ye Y; Gaudy A; Ghosh A; Xue Y; Wang A; Zhou S; Li Y
    Clin Pharmacol; 2023; 15():9-19. PubMed ID: 36880014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
    Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
    Li Y; Kassir N; Wang X; Palmisano M; Zhou S
    J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
    Lonial S; Popat R; Hulin C; Jagannath S; Oriol A; Richardson PG; Facon T; Weisel K; Larsen JT; Minnema MC; Abdallah AO; Badros AZ; Knop S; Stadtmauer EA; Cheng Y; Amatangelo M; Chen M; Nguyen TV; Amin A; Peluso T; van de Donk NWCJ
    Lancet Haematol; 2022 Nov; 9(11):e822-e832. PubMed ID: 36209764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
    Dosne AG; Li X; Luo MM; Nnane I; Dimopoulos MA; Terpos E; Sonneveld P; Kampfenkel T; Carson R; Amin H; Perez Ruixo J; Zhou H; Sun YN; Xu Y
    Br J Clin Pharmacol; 2023 May; 89(5):1640-1655. PubMed ID: 36484341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
    Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L
    Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of CC-122.
    Cheng Y; Chen J; Pourdehnad M; Zhou S; Li Y
    Clin Pharmacol; 2021; 13():61-71. PubMed ID: 33958900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I, Open-Label, Mass Balance Study of [
    Cheng Y; Wang X; Liu L; Silva J; Thomas M; Li Y
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):355-365. PubMed ID: 38521893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
    Hoeben E; De Winter W; Neyens M; Devineni D; Vermeulen A; Dunne A
    Clin Pharmacokinet; 2016 Feb; 55(2):209-23. PubMed ID: 26293616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of lenalidomide in multiple myeloma patients.
    Guglieri-López B; Pérez-Pitarch A; Moes DJ; Porta-Oltra B; Climente-Martí M; Guchelaar HJ; Merino-Sanjuán M
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):189-200. PubMed ID: 28039509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
    Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
    Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
    Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies.
    Connarn JN; Hwang R; Gao Y; Palmisano M; Chen N
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):465-473. PubMed ID: 28724202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
    Edlund H; Bellanti F; Liu H; Vishwanathan K; Tomkinson H; Ware J; Sharma S; Buil-Bruna N
    Br J Clin Pharmacol; 2022 Feb; 88(2):846-852. PubMed ID: 34265100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
    Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
    Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.
    Chien YH; Würthwein G; Zubiaur P; Posocco B; Pena MÁ; Borobia AM; Gagno S; Abad-Santos F; Hempel G
    Cancer Chemother Pharmacol; 2022 Aug; 90(2):125-136. PubMed ID: 35831644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive population pharmacokinetic modelling of sugemalimab, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I-III studies.
    Wang K; Pan C; Xu F; Tse AN; Sheng Y
    Br J Clin Pharmacol; 2024 Oct; ():. PubMed ID: 39389094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.